September 9, 2021 – Same-day discharge after total knee arthroplasty (TKA) or total hip arthroplasty (THA) is safe in some patients classified as “high risk” – with no increase in complications or other adverse outcomes, reports a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
In patients undergoing TKA or THA, “We found that same-day discharge did not increase the risk of emergency department visits, unplanned readmissions, and complications as compared with an inpatient stay for higher-risk patients, suggesting that it is possible to expand indications for same-day discharge in the hospital setting while maintaining safety,” according to the new research by Nithin C. Reddy MD of the Southern California Permanente Medical Group, San Diego, and colleagues.
Same-day discharge after TKA/THA is ‘not inferior’ to inpatient surgery in patients with ASA grade ≥3
The cohort study included two groups of “high-risk” patients who underwent THA (5,250 patients) or TKA (9,752 patients) for osteoarthritis, identified with use of the Kaiser Permanente Total Joint Replacement Registry. All patients had an American Society of Anesthesiologists (ASA) classification of 3 or higher, indicating a higher risk of adverse outcomes related to surgery and anesthesia. Common conditions in this ‘higher risk’ cohort included high blood pressure, obesity, and diabetes.
In both the THA and TKA groups, about one-third of patients were discharged on the same day as surgery, without spending a night in the hospital. Complication rates, emergency department (ED) visits, unplanned hospital readmissions, and mortality were compared for patients who underwent same-day or inpatient surgery.
For high-risk patients undergoing THA, same-day discharge was shown to be noninferior to inpatient surgery for most outcomes. At 90 days, same-day discharge showed no increase in complications, ED visits, or hospital readmissions. The study could not demonstrate noninferiority for mortality, as death was uncommon within 90-days post-discharge in both groups.
For patients undergoing TKA, same-day discharge was shown to be noninferior to inpatient surgery for mortality as well as complications, ED visits, and hospital readmissions. For both THA and TKA, the authors were unable to rule out a higher risk of certain types of complications, specifically deep infections and clot-related complications. Both of these complications occurred in less than one percent of patients in both groups.
Certain other medical conditions were associated with an increased risk of specific adverse outcomes following same-day discharge. For example, patients with congestive heart failure had significantly higher complication rates after both THA and TKA. Other medical conditions were also associated with increased rates of ED visits and hospital readmission. Black patients had a higher risk of ED visits following TKA with same-day discharge.
All patients were treated at Kaiser Permanente hospitals in California, where formal programs have been introduced for same-day rapid recovery following total joint replacement, including preoperative education, case managers, and home health. Before discharge, patients had to meet specific requirements for pain control, mobility, and caregiver support.
Previous studies have reported that same-day discharge following THA or TKA is safe for healthy patients, leading to significant cost savings. Most of these studies have been limited to relatively younger and healthier patients. Concerns about safety, along with potential financial penalties for patients requiring further care, have so far limited expansion of same-day discharge in higher-risk patients.
The new study supports the feasibility and safety of same-day discharge for one group of higher-risk patients: those with an ASA score of 3 or higher. “Our findings suggest that it may be possible to expand the indications for same-day discharge [TKA or THA] to include more a more diverse selection of patients, provided that robust, enhanced care protocols are in place to ensure patient safety and mitigate the risk of adverse events,” Dr. Reddy and colleagues conclude. They emphasize the need for larger studies to evaluate the impact on less-frequent outcomes.
DOI: 10.2106/JBJS.20.02110
###
About The Journal of Bone & Joint Surgery
The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.
About Wolters Kluwer
Wolters Kluwer (WKL) is a global leader in professional information, software solutions, and services for the clinicians, nurses, accountants, lawyers, and tax, finance, audit, risk, compliance, and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with advanced technology and services.
Wolters Kluwer reported 2020 annual revenues of €4.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 19,200 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
For more information, visit www.wolterskluwer.com, follow us on Twitter, Facebook, LinkedIn, and YouTube.
